Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: Results from the UK General Practice Research Database (GPRD)

Rheumatology

Volumn 44, Issue 8, 2005, Pages 1038-1042

  Mikuls, T R ^a,b   Farrar, J T ^c   Bilker, W B ^c   Fernandes, S ^c   Saag, K G ^d,e  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Allopurinol; Asymptomatic hyperuricaemia; Gout; GPRD; Medical error; Quality indicator; Quality of care

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; CYCLOSPORIN; DIURETIC AGENT; MERCAPTOPURINE; TACROLIMUS; ANTIGOUT AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE REGIMEN; DRUG QUALITY; DRUG USE; FACTUAL DATABASE; FEMALE; FOLLOW UP; GENERAL PRACTICE; GOUT; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; SEX DIFFERENCE; SOCIAL ASPECT; SYMPTOMATOLOGY; UNITED KINGDOM; VALIDATION PROCESS; CLINICAL PRACTICE; CLINICAL TRIAL; DATA BASE; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE; STANDARD; STATISTICS;

ADULT; AGED; ALLOPURINOL; DATABASES; FAMILY PRACTICE; FEMALE; GOUT; GOUT SUPPRESSANTS; GREAT BRITAIN; GUIDELINE ADHERENCE; HUMANS; HYPERURICEMIA; MALE; MEDICATION ERRORS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; QUALITY INDICATORS, HEALTH CARE;

EID: 24944435549     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh679     Document Type: Article

References (28)

1. Mikuls T, Farrar J, Bilker W, Fernandes S, Schumacher H Jr, Saag K. Gout epidemiology: Results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72.
2. Hande K, Noone R, Stone W. Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
3. Devlin J, Bellamy N, Bayliff C. Observations and effects of educational consults on allopurinol prescribing. Can J Hosp Pharm 1992;45:21-7.
4. Smith P, Karlson N, Nair B. Quality use of allopurinol in the elderly. J Qual Clin Pract 2000;20:42-3.
5. Stamp L, Gow P, Sharples K, Raill B. The optimal use of allopurinol: An audit of allopurinol use in South Auckland. Aust N Z J Med 2000; 30:567-72.
6. Mikuls T, MacLean CH, Olivieri J et al. Quality of care indicators for gout management. Arthritis Rheum 2004;50:937-43.
7. Shekelle P, MacLean CH, Morton SC, Wenger NS. Assessing care of vulnerable elders: Methods for developing quality indicators. Ann Intern Med 2001;135(Suppl.):647-52.
8. Garcia Rodriguez L, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25.
9. Jick H, Jick S, Derby L. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991;302:766-8.
10. Perry J. Oxmis problem code for primary medical care. Oxford: Oxmis Publications, 1971.
11. Onder G, Landi F, Cesari M, Gambassi G, Carbonin P, Bernabei R. Investigators of the GIFA Study. Inappropriate medication use among hospitalized older adults in Italy: Results from the Italian Group of Pharmacoepidemiology in the Elderly. Eur J Pharmacol 2003;59:157-62.
12. Mamun K, Lien CT, Goh-Tan CY, Ang WS. Polypharmacy and inappropriate medication use in Singapore nursing homes. Ann Acad Med Singapore 2004;33:49-52.
13. Kennedy D, Hayney M, Lake K. Azathioprine and allopurinol: The price of an avoidable drug interaction. Ann Pharmacother 1996; 30:951-4.
14. Venkat Raman G, Sharman V, Lee H. Azathioprine and allopurinol: A potentially dangerous combination. J Intern Med 1990;228:69-71.
15. Hochberg M, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout: The role of hypertension. Arthritis Rheum 1995;38:628-32.
16. Campion E, Glynn R, DeLabry L. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6.
17. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA 1991;266:3004-7.
18. Hahn P, Edwards L. Management of hyperuricemia. In: Koopman W, Moreland L, eds. Arthritis and allied conditions: A textbook of rheumatology. Philadelphia: Lippincott Williams & Wilkins, 2004: 2341-55.
19. Stuart RA, Gow PJ, Bellamy N, Campbell J, Grigor R. A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis. N Z Med J 1991;104:115-7.
20. Woo J, Swaminathan R, Cockram C, Lau E, Chan A. Association between serum uric acid and some cardiovascular risk factors in a Chinese population. Postgrad Med J 1994;70:486-91.
21. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: Findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989;42:257-67.
22. Freedman D, Williamson DF, Gunter EW. Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995;141:637-44.
23. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricemia and risk of cardiovascular disease and overall health. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988;224:549-55.
24. Abbott R, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: The Framingham Study. J Clin Epidemiol 1988; 41:237-42.
25. Fang J. Alderman M. Serum uric acid and cardiovascular mortality: NHANES I epidemiologic follow-up study, 1971-1992. JAMA 2000; 283:2404-10.
26. Currie W. Prevalence and incidence of the diagnosis of gout in Great Britain. Ann Rheum Dis 1979;38:101-6.
27. Harris C, Lloyd C, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995;48:1153-8.
28. Roberts C, Adebajo A, Long S. Improving the quality of care of musculoskeletal conditions in primary care. Rheumatology 2002; 41:503-8.